ArticleFrontiers in toxicology2026
Zebrafish neuromast development: a target for endocrine disrupting chemicals?
Article in Frontiers in toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In response to increasing evidence of human and environmental health impacts of endocrine disrupting chemicals (EDCs), screening and testing programs for EDC assessment are being developed, requiring characterization of potential adverse health effects. The development of the lateral line (LL), a neurosensory system in fish, has been suggested as a potential toxicological target of EDCs. The LL contains neuromasts with hair cells (HCs) which convert mechanical stimuli into neural signals. An exploratory study was performed to assess whether neuromast development is affected by a selection of model EDCs with different modes of action. Zebrafish embryos were exposed to EDCs, targeting estrogen and thyroid pathways, immediately after fertilization. The number of HCs in four neuromasts was counted at 120 h post fertilization. Methimazole and resorcinol (thyroid hormone [TH] synthesis inhibitors) elicited the strongest response, characterized by a reduction in HC numbers, while fulvestrant (anti-estrogen) slightly increased HC numbers. Further investigation confirmed a reduction of HCs and neuromasts after exposure to methimazole during late embryonic development, when TH synthesis is active. Gene transcript level analysis revealed a decreased marker for HC activity and increased markers of support cells, essential for HC regeneration. Taken together, neuromast development appears to be affected by certain EDCs in zebrafish embryos, at concentrations similar to those causing other effects (e.g., impaired swim bladder inflation). However, variability in the responses complicates characterization using the FM1-43 method. Further research, including rescue experiments and more sensitive or functionally relevant methods, is needed to clarify the mechanisms underlying EDC-induced HC disruption.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.